A facility dedicated to Millipore® CTDMO in Martillac

In Martillac, France, Merck has just opened a new 2,700 m2 facility dedicated to the operations of Millipore® CTDMO, which offers services from pre-clinical to commercial phases in the field of biotechnology.
Featuring state-of-the-art equipment and experts, the fully integrated facility is designed to offer capacities from 200 to 2,000 liters with two 2,000-liter bioreactors.
The facility provides for global supply with the production of monoclonal antibodies and recombinant proteins. This new offer, eliminating the need of technology transfer, will rationalize and accelerate the process of product development and commercialization to reduce by half the time needed to bring biological products to market.
In order to meet the demand of the science sector, other expansion projects are also under consideration at Merck, which plans to significantly increase its investments until 2025 to achieve its growth objectives in the US, Europe and China.